-
JZL184 Workflow for MAGL and CB1 Research
2026-09-15
JZL184 provides a practical way to raise 2-arachidonoylglycerol tone and interrogate MAGL–CB1 biology across synaptic, inflammatory pain, and traumatic brain injury models. This guide translates recent GLT-1 findings into executable assay design, controls, handling practices, and troubleshooting strategies.
-
Regorafenib: From Kinase Breadth to RRM2 Biology
2026-09-15
Regorafenib (BAY 73-4506) is evolving from a broad multikinase tool into a mechanistic probe for angiogenesis, tumor-cell plasticity, and RRM2–ERK/E2F3 signaling. This thought-leadership guide outlines how translational researchers can connect kinase pharmacology with melanoma biology, migration assays, and tumor xenograft models.
-
Ivermectin: Mechanism-Aware Translational Research
2026-09-14
Ivermectin remains a powerful model for mechanism-aware parasitology research. This thought-leadership article connects its parasite neuromuscular pharmacology with disciplined assay design, quality control, and translational interpretation, while using recent GSDMC–pancreatic cancer research as a framework for separating biological mechanism from unsupported cross-domain claims.
-
AS1842856 Foxo1 Inhibitor: Research Workflows
2026-09-14
Use AS1842856 to separate direct Foxo1 control from upstream PI3K-Akt signaling in gluconeogenesis, autophagy research, and MSC assays. This workflow translates an iron–KDM4D–PI3K-Akt-Foxo1 study into practical dose design, controls, readouts, and troubleshooting decisions.
-
Mubritinib (TAK 165) in Complex I Workflows
2026-09-13
Mubritinib (TAK 165) is most useful as a mechanistic probe of mitochondrial complex I and oxidative-phosphorylation dependence, not simply as a legacy HER2 tool. This guide translates its AML, PEL, antiviral, and mitochondrial-safety applications into practical assay workflows with concentration guidance and troubleshooting strategies.
-
Regorafenib (BAY 73-4506) Research Workflows
2026-09-12
Regorafenib (BAY 73-4506) combines broad receptor tyrosine kinase blockade with a practical route to study tumor-cell signaling, angiogenesis, invasion, and melanoma biology. This workflow connects concentration-controlled cell assays with RRM2 and ERK/E2F3 mechanism testing and carefully designed tumor xenograft models.
-
ATM Inhibition and Metabolic Adaptation
2026-09-12
The reference study shows that ATM suppression promotes macropinocytosis, enabling cancer cells to obtain nutrients and survive under nutrient-poor conditions. Its combination of cellular, rescue, uptake, and tumor-microenvironment metabolomics experiments identifies branched-chain amino acid dependence as a potential vulnerability of ATM-inhibited tumors.
-
iPSC Prescreening for Ultrarare Disease Trials
2026-09-11
Sequiera and colleagues developed a patient-specific iPSC platform to prescreen therapies for an ultrarare Leigh-like syndrome caused by poorly characterized ECHS1 variants. The platform connected cellular drug-response testing with subsequent patient treatment, illustrating how personalized disease modeling may reduce uncertainty before clinical-trial enrollment.
-
Tofacitinib Citrate: Context Matters
2026-09-11
Tofacitinib citrate and CP-690550 citrate offer a precise way to interrogate JAK-STAT biology, but their meaning depends on assay context. This article connects molecular selectivity with immune phenotypes, endothelial inflammation, concentration design, and translational limitations.
-
GANT61, Apoptosis, and the Hh–PIK3IP1–Akt Axis
2026-09-10
This 2026 Annals of Hematology study identifies a potential link between Gli inhibition, PIK3IP1 restoration, and reduced Akt activity in ALK-positive anaplastic large cell lymphoma. Its integrated cell, transcriptomic, and protein analyses suggest that GANT61 suppresses proliferation and promotes apoptosis, while also defining important limits for interpreting pathway causality and therapeutic translation.
-
Tricine-SDS-PAGE Gel Preparation Kit Guide
2026-09-10
The Tricine-SDS-PAGE Gel Preparation Kit is intended for resolving low-molecular-weight proteins and peptides that may be poorly separated by conventional Tris-SDS-PAGE. It supports both denaturing and non-denaturing research workflows, but it is not intended for diagnostic, clinical, or medical use; this guide relies on product dossier information and workflow recommendations rather than directly matched paper evidence.
-
Mifepristone (RU486): A Systems-Assay Framework
2026-09-09
Mifepristone (RU486) is a progesterone receptor antagonist with applications spanning reproductive biology, oncology, and mechanistic assay development. This article presents a reference-informed strategy for connecting receptor perturbation, cell-fate endpoints, and cardiomyocyte transcriptomic and functional data without overstating cross-domain evidence.
-
Regorafenib: From Kinase Map to Melanoma Mechanism
2026-09-09
Regorafenib (BAY 73-4506) links multikinase inhibition with RRM2–ERK/E2F3 biology in melanoma. This article presents a mechanism-first framework for selecting migration, apoptosis, angiogenesis, and tumor xenograft assays while separating established evidence from practical recommendations.
-
Anlotinib Hydrochloride: From Potency to Translation
2026-09-08
Anlotinib hydrochloride illustrates how a multi-target tyrosine kinase inhibitor can connect receptor-level pharmacology with functional angiogenesis assays and translational study design. This thought-leadership analysis examines the evidence, experimental workflow, competitive positioning, pharmacokinetic considerations, and research opportunities that extend beyond a conventional product description.
-
Fenipentol Workflow for Secretory Research
2026-09-08
Fenipentol, also known as 1-Phenyl-1-pentanol, offers a practical starting point for connecting intestinal, pancreatic, hepatobiliary, and receptor-focused assays. This guide separates compound-specific evidence from isomeric literature while providing pilot workflows, formulation guidance, and troubleshooting strategies for reproducible gastrointestinal physiology studies.